Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 404

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 404
---

    Proceeds from exercise of stock options and purchase of stock under the     Employee Stock Purchase Program

    79,525

    51,246

    30,043

    Payment on maturity of 2024 Notes

    (68
    )

    —

    —

    Debt conversion costs for 2024 Notes

    —

    (6,887
    )

    —

    Proceeds from 2027 Notes offering, net of commissions

    —

    —

    1,127,400

    Purchase of capped call share options for 2027 Notes

    —

    —

    (127,305
    )

    Debt issuance costs for 2027 Notes

    —

    —

    (716
    )

    Repurchase of 2024 Notes

    —

    —

    (247,868
    )

    Repayment of principal amount due under 2019 Term Loan

    —

    —

    (550,000
    )

    Payment on debt extinguishment of 2019 Term Loan

    —

    —

    (25,364
    )

    Net cash provided by financing activities

    124,806

    125,004

    232,507

    Increase (decrease) in cash and cash equivalents

    674,580

    (541,792
    )

    (1,139,722
    )

    Cash, cash equivalents and restricted cash:

    Beginning of year

    444,009

    985,801

    2,125,523

    End of year
     
    $
    1,118,589

    $
    444,009

    $
    985,801

    Reconciliation of cash, cash equivalents and restricted cash:

    Cash and cash equivalents
     
    $
    1,103,010

    $
    428,430

    $
    966,777

    Restricted cash in other assets

    15,579

    15,579

    19,024

    Total cash, cash equivalents and restricted cash
     
    $
    1,118,589

    $
    444,009

    $
    985,801

    Supplemental disclosure of cash flow information:

    Cash paid during the period for interest
     
    $
    15,856

    $
    15,923

    $
    44,418

    Cash paid during